1000565-32-1 Usage
Description
(6-Trifluoromethyl-pyridin-2-yl)-acetic acid is an organic compound characterized by the presence of a trifluoromethyl group attached to a pyridine ring, which is further connected to an acetic acid moiety. This unique molecular structure endows it with specific chemical properties that make it suitable for various applications, particularly in the synthesis of other compounds.
Uses
Used in Pharmaceutical Industry:
(6-Trifluoromethyl-pyridin-2-yl)-acetic acid is used as a key intermediate in the synthesis of oxadiazole derivatives, which are known for their broad-spectrum antimicrobial properties. These derivatives are valuable as microbicides, playing a crucial role in the development of new antimicrobial agents to combat drug-resistant infections.
Used in Chemical Synthesis:
In the field of organic chemistry, (6-Trifluoromethyl-pyridin-2-yl)-acetic acid serves as a versatile building block for the preparation of a wide range of chemical compounds. Its reactivity and functional groups make it an attractive candidate for further chemical modifications, leading to the creation of new molecules with potential applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1000565-32-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,0,5,6 and 5 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1000565-32:
(9*1)+(8*0)+(7*0)+(6*0)+(5*5)+(4*6)+(3*5)+(2*3)+(1*2)=81
81 % 10 = 1
So 1000565-32-1 is a valid CAS Registry Number.
InChI:InChI=1S/C8H6F3NO2/c9-8(10,11)6-3-1-2-5(12-6)4-7(13)14/h1-3H,4H2,(H,13,14)
1000565-32-1Relevant articles and documents
Discovery of GSK2656157: An optimized PERK inhibitor selected for preclinical development
Axten, Jeffrey M.,Romeril, Stuart P.,Shu, Arthur,Ralph, Jeffrey,Medina, Jesus R.,Feng, Yanhong,Li, William Hoi Hong,Grant, Seth W.,Heerding, Dirk A.,Minthorn, Elisabeth,Mencken, Thomas,Gaul, Nathan,Goetz, Aaron,Stanley, Thomas,Hassell, Annie M.,Gampe, Robert T.,Atkins, Charity,Kumar, Rakesh
supporting information, p. 964 - 968 (2013/10/22)
We recently reported the discovery of GSK2606414 (1), a selective first in class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK), which inhibited PERK activation in cells and demonstrated tumor growth inhibition in a human tumor xenograft in mice. In continuation of our drug discovery program, we applied a strategy to decrease inhibitor lipophilicity as a means to improve physical properties and pharmacokinetics. This report describes our medicinal chemistry optimization culminating in the discovery of the PERK inhibitor GSK2656157 (6), which was selected for advancement to preclinical development.
